4 views left Get unlimited views with a free account

Explore the latest trends and actionable insights on the Epidermolysis Bullosa Pipeline Drugs to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Epidermolysis Bullosa by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 31 ongoing clinical trials involving Epidermolysis Bullosa
Of the 31 trials,14 trials are in Phase I/II
Furthermore, 9 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Epidermolysis Bullosa by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Epidermolysis Bullosa, a dermatology condition. The largest number of ongoing clinical trials for Epidermolysis Bullosa is conducted in North America. Europe and Asia-Pacific are among some of the other prominent regions engaged in Epidermolysis Bullosa-related drug trials.

Epidermolysis Bullosa related clinical trials sponsors

Holostem Terapie Avanzate SRL, University of Southern California, Masonic Cancer Center, Castle Creek Biosciences Inc, and Krystal Biotech Inc are a few notable clinical trials sponsors involving Epidermolysis Bullosa. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Epidermolysis Bullosa

Betamethasone butylates propionate (Antebate) and Mupirocin (Bactroban, Mupiskin, Mupiderm) are key marketed drugs involving Epidermolysis Bullosa.

Betamethasone butylate propionate (Antebate) Is a corticosteroid, anti-inflammatory drug,’ and an immunosuppressive agent. It functions via Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1) Agonist mechanism of action. It is formulated as a cream, ointment, lotion for topical application. Antebate is indicated for the treatment of eczema, dermatitis group, psoriasis, insect bites, drug eruption-poisoning rash, prurigo group, erythroderma, erythema, dowels rose pityriasis, palmoplantar pustulosis, flat red lichen, chronic discoid lupus erythematosus, granuloma disease, idiopathic pigmented purpura, alopecia areata, hypertrophic scars, keloid, malignant lymphoma, lichen amyloidosis, bullosa. Betamethasone butylate propionate was first approved in 2001 and is marketed in Japan by Torii Pharmaceutical Co Ltd.

Mupirocin (Bactroban, Mupiskin, Mupiderm) is an antibiotic agent which is isolated from Pseudomonas fluorescens. It functions via Isoleucine tRNA Ligase Cytoplasmic (Isoleucyl tRNA Synthetase or IARS or EC 6.1.1.5) Inhibitor mechanism of action. It is formulated as an ointment, cream for topical and cutaneous administration, ointment for nasal administration. The Bactroban nasal ointment is indicated for the eradication of nasal colonization with methicillin-resistant Staphylococcus aureus (MRSA) in adult and pediatric patients (aged 12 years and older) and healthcare workers as part of a comprehensive infection control program to reduce the risk of infection among patients at high risk of MRSA infection during institutional outbreaks of infections with this microorganism. Mupirocin was first approved in 1985 and is marketed globally including the US, the UK, Australia, Germany, China, and Japan by GlaxoSmithKline LLC.

Explore the latest trends and actionable insights on the Epidermolysis Bullosa Pipeline Drugs to inform business strategy and pinpoint opportunities and risks. Explore the latest trends and actionable insights on the Epidermolysis Bullosa Pipeline Drugs to inform business strategy and pinpoint opportunities and risks. Visit Report Store